ICU Medical is due to report November 5, 2026: what it means for ICU Medical stock
Published on 10/15/2026 at 21:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults date and valuation
- MarketBeat estimates that ICU Medical will report third-quarter results on November 5, 2026.
- Revenue reached USD 551.70 million in the second quarter of 2026.
- ICU Medical stock costs EUR 148.50 at Lang & Schwarz on October 15, 2026 at 9:11 p.m. CEST.
- ICU Medical trades at a P/E ratio of 141.22 with a market capitalization of USD 4.2 billion.
ICU Medical is estimated to report third-quarter 2026 results on November 5, 2026, according to MarketBeat. The stock was trading at EUR 148.50 at Lang & Schwarz on October 15, 2026 at 9:11 p.m. CEST.
Second-quarter revenue reached USD 551.70 million
ICU Medical reported revenue of USD 551.70 million in the second quarter of 2026. The figure comes from the latest reported period and provides the operating baseline before the November update, while adjusted earnings per share for that quarter stood at USD 2.37, according to Simply Wall St.
Price position and trading range
The Nasdaq-listed medical technology company was last quoted at USD 166.66 on October 15, 2026 at 3:19 p.m. EDT. That was USD 3.97 above the prior Nasdaq close of USD 162.69, equivalent to a 2.44 percent increase on the home exchange. ICU Medical's session range was USD 164.10 to USD 167.72, while the 52-week range was USD 107.00 to USD 192.85.
The company had reported its second-quarter results on August 6, 2026. The next report date is estimated rather than confirmed in the earnings calendar, and MarketBeat lists expected third-quarter revenue of USD 552.07 million against USD 533.30 million in the comparable prior-year quarter, a 3.52 percent increase.
Valuation and operating profile
ICU Medical had a market capitalization of USD 4.2 billion and a P/E ratio of 141.22 on October 15, 2026. Its average trading volume was 273,853 shares, compared with 139,525 shares in the latest session. The company develops infusion therapy and critical-care products, including smart pumps, connectors and vascular-access devices, as described by ICU Medical.
Comparison with peers
ICUI: plus 2.44 percent, P/E 141.22, market capitalization USD 4.2 billion
Merit Medical Systems (Nasdaq, USD): plus 2.61 percent, P/E 36.95, market capitalization USD 5.3 billion
Insulet (Nasdaq, USD): plus 3.38 percent, P/E 25.88, market capitalization USD 9.6 billion
Upcoming results set the next date
The November 5 reporting date gives investors the next scheduled checkpoint for revenue, earnings and management's view of the full-year outlook. ICU Medical's latest quarter showed USD 551.70 million in revenue, while the market calendar points to USD 552.07 million for the third quarter.
ICU Medical stock stays near its yearly high
The stock's USD 192.85 52-week high is USD 26.19 above the latest Nasdaq quote of USD 166.66. The separate euro quotation reflects the German trading perspective, while the Nasdaq figures describe the company's home listing.
The further course of trading is shown by the continuously updated real-time quote of ICU Medical stock.
ICU Medical stock at a glance
- Company: ICU Medical, Inc.
- ISIN: US44930G1076
- Ticker: ICUI
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:11 p.m. CEST): EUR 148.50
- Market capitalization: USD 4.2 billion (as of October 15, 2026)
- 52-week range: USD 107.00-192.85 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical - Instruments & Supplies
- Next earnings date: November 5, 2026
Market context: Market report S&P 500.
